相关实验视频

Updated: May 31, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

在MET放松调节的NSCLC患者中探索不同治疗方法的实践经验:从现实世界的回顾性分析

Mengmeng Li¹, Jiuyan Huang¹, Ruyue Xing²

¹Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 127 Dong Ming Road, Zhengzhou, 450008, China.

BMC pulmonary medicine

|January 25, 2025

概括

针对介质细胞转移因子 (MET) 的向疗法改善了METex14跳转突变的非小细胞肺癌 (NSCLC) 患者的治疗结果,特别是那些具有拼接供体突变的患者. 双目标疗法优于单一疗法,用于EGFR-TKI抵抗后的二次MET放大.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

在非小细胞肺癌 (NSCLC) 中,介质到上皮过渡因子 (MET) 调节失调尚未得到研究.
关于MET变异的NSCLC患者治疗结果的数据有限.

研究的目的:

为了研究METex14跳转突变和MET放大的NSCLC患者的治疗结果.
为了比较不同疗法的疗效,包括化疗,免疫疗法,克里佐替尼布和萨沃利提尼布.

主要方法:

160名患有初级或二级MET变化的NSCLC患者的回顾性分析.
患者接受了各种治疗:化疗,免疫疗法,克里佐替尼布或萨沃利提尼布.
生存分析包括了130名完成治疗的患者.

主要成果:

对于METex14跳转突变,向疗法 (萨沃利替尼布9.3m,克里佐替尼布8.5m) 和化疗 (7.64m) 的表现优于免疫疗法 (3.87m). 拼接供体突变显示出更好的PFS (9.23m) 比多胺系突变 (4.03m).
对于初级MET放大,Savolitinib (5.23m) 和Crizotinib (3.80m) 显示了比化疗 (2.84m) 更长的PFS. 较高的副本数量 (CN>5) 与较长的PFS (5.17m vs 3.44m) 相相关.
对于二次MET放大,双目标疗法 (A组和B组:6.77m和6.57m) 优于Crizotinib单一疗法 (C组:3.13m),无论副本数量如何.

结论:

具有METex14跳转突变的NSCLC患者从向疗法中获益最多,特别是那些具有拼接供体突变的患者.
MET放大患者普遍受益于向治疗,更高的副本数量显示了初级放大疗法的改善结果.
在EGFR-TKI耐药性后的二次MET放大中,双重向疗法比Crizotinib单一疗法更有效.

关键词:

克里佐丁尼布 (crizotinib) 是一种可以中介细胞-上皮细胞过渡因子.非小细胞肺癌是非小细胞肺癌.萨沃利提尼布 (Savolitinib) 是一种药物.

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Kaplan-Meier Approach

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...